# Capricor Therapeutics share price today (Capricor Therapeutics, Inc., CAPR)

> Capricor Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CAPR · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/capr

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $8.92 (+50.4% in a year)
- Revenue (Dec 2024): $11.1 M (−7.9% on a year ago)
- Profit (Dec 2024): −$7.1 M
- Operating margin: −69.1% (−58.5 points on a year ago)
- ROE: −28%, FY24
- ROIC: −38.1%, against a 7.6% cost of capital: −45.7 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Capricor Therapeutics share price today? Capricor Therapeutics, Inc.'s share price was $8.92 at the close on 4 November 2026. That is 56.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $4 and $35, and at that close it sat 16% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 1 year the share price moved +17% while the S&P 500 moved +18%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Capricor Therapeutics pay? Capricor Therapeutics, Inc. pays no dividend. In the last 11 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Capricor Therapeutics on? Capricor Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Capricor Therapeutics profitable? Capricor Therapeutics, Inc. posted a net loss of $7.1 M in the Dec 2024 quarter. The full FY24 year was a loss of $40.5 M. That loss is 63.9% of the quarter's revenue. The same quarter a year earlier lost $762 K. 11 of the last 11 reported quarters were loss-making. ## How much revenue does Capricor Therapeutics make, and is it growing? Capricor Therapeutics, Inc. reported $11.1 M of revenue in the Dec 2024 quarter, −7.9% on the same quarter a year earlier. Over 3 years it has grown 349.6% a year on average. The last full year, FY24, came in at $22.3 M. The last four reported quarters add to $22.3 M. FY24 revenue was $22.3 M, −11.5% on the year before. Recent pace: the last four quarters grew −1.4% on average, against 349.6% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every $100 of sales does Capricor Therapeutics keep? Capricor Therapeutics, Inc.'s operating margin was −69.1% in the Dec 2024 quarter, 58.5 percentage points lower than the same quarter a year ago. Across 4 years it has been between −8,546.1% and −95.6%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed −58.5 percentage points on the year while gross margin changed −48.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Capricor Therapeutics' profit turning into cash? Capricor Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY24 its operations used $40.0 M of cash, against −$40.5 M of profit. After $1.5 M of spending on assets, free cash was −$41.5 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Capricor Therapeutics' cash go? Capricor Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $6.9 M on assets over the last 3 years. Averaged over those years that is 10.4% of FY24 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $6.9 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Capricor Therapeutics' P/E ratio, and how does it compare with its own history? Capricor Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Capricor Therapeutics, Inc. at 23.3× its FY24 revenue of $22.3 M. The P/E comes back here once profit turns positive. ## Is the Capricor Therapeutics business getting better or worse? Capricor Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Capricor Therapeutics earn on its capital? Capricor Therapeutics, Inc. earned a ROE of −28% in FY24. That is up from a low of −246% in FY22. Its return on capital used (ROIC) is 45.7 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −181.7% net margin and 0.13× asset turnover (sales divided by assets). Why the return is what it is (FY24): a −181.7% net margin × 0.13× asset turnover × 1.17× leverage (assets divided by equity) ≈ −27.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −38.1% − 7.6% = −45.7 percentage points. The 7.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Capricor Therapeutics have too much debt? Capricor Therapeutics, Inc. has total debt of $91.0 M against shareholder equity of $246 M as of Jun 2026, so its debt is 0.37× its equity. Year by year, that ratio went from 0.09 in FY21 to 0.05 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Capricor Therapeutics shareholding pattern? 43.6% of Capricor Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Capricor Therapeutics from balance-sheet trouble? For Capricor Therapeutics, Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Capricor Therapeutics rank in its industry? There is no score against its industry: Capricor Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Capricor Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Capricor Therapeutics in size? Capricor Therapeutics is the 140th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Puma Biotechnology, Inc., Valneva SE and Ovid Therapeutics Inc. Just below it: Shattuck Labs, Inc., CytomX Therapeutics, Inc. and REGENXBIO Inc. ### Biotechnology companies close in size

1. [Puma Biotechnology, Inc.](https://www.sectoralpha.in/us/stocks/pbyi) $552 million
2. [Valneva SE](https://www.sectoralpha.in/us/stocks/valn) $539 million
3. [Ovid Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/ovid) $535 million
4. Capricor Therapeutics, Inc. $519 million
5. [Shattuck Labs, Inc.](https://www.sectoralpha.in/us/stocks/sttk) $517 million
6. [CytomX Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ctmx) $512 million
7. [REGENXBIO Inc.](https://www.sectoralpha.in/us/stocks/rgnx) $509 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Malibu Boats, Inc.](https://www.sectoralpha.in/us/stocks/mbuu) $481 million · Recreational Vehicles
2. [ACCO Brands Corporation](https://www.sectoralpha.in/us/stocks/acco) $479 million · Business Equipment & Supplies
3. Capricor Therapeutics, Inc. $479 million
4. [Gray Media, Inc.](https://www.sectoralpha.in/us/stocks/gtn-a) $479 million · Broadcasting
5. [One Liberty Properties, Inc.](https://www.sectoralpha.in/us/stocks/olp) $479 million · REIT - Diversified

## What else do people ask about Capricor Therapeutics? ### What were Capricor Therapeutics's latest quarterly results? Capricor Therapeutics, Inc. reported revenue of $11.1 M and a net loss of $7.1 M for the Dec 2024 quarter. Earnings per share were −$0.16. The operating margin was −69.1%, 58.5 percentage points lower than a year earlier (as of 4 November 2026). ### What is Capricor Therapeutics's market cap? Capricor Therapeutics, Inc.'s market capitalisation is $519 M at a stock price of $8.92. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Capricor Therapeutics performing? Capricor Therapeutics, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Capricor Therapeutics's stock price go up? This page does not forecast Capricor Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $8.92. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Capricor Therapeutics in its business cycle? Capricor Therapeutics, Inc.'s FY24 operating margin was −191.1%, against a 4-year range of −8,546.1% to −95.6%: the middle of its own range, neither a peak nor a low. The latest quarter was −69.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Capricor Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Capricor Therapeutics a stock worth studying right now? What the numbers show: Capricor Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.